Thesis
Author: Freeman LewinEvents
Our read
Our read
FDA moved on trial design in one week: finalised guidance broadening cancer-trial eligibility, a rewritten Alzheimer's design and a rare-disease framework, while the EMA makes its flexible EU pilot permanent. Sponsors answer by editing protocols, which widens each site's pre-screened pool without adding site staff, so activation queues and screen failures become the binding constraint on readouts. Falsified if eligibility-criterion text, recruiting-site counts and first-patient-in intervals stop moving after the guidance dates. Test it with protocol-registry criterion diffs and per-site status records plus site activation logs.
EHR based clinical trial prescreening platform enrollment data
Guidance, not a molecule, is what moved trial design this week, so the observable is protocol text and site-status history rather than pipeline announcements; the 'sponsors haven't caught up' gap is exactly the lag a criterion-diff panel would date.
earnings-language deltaclinicaltrialvanguard.com
The same week's operational reporting names activation workflow, not patient supply, as the quoted bottleneck; if that is the true gate, loosened eligibility adds queue length rather than enrolments, which is the falsifiable half of the claim.
operating-metric inflectionclinicaltrialvanguard.com
Broadening who may enrol (organ-function, brain-metastasis, prior-therapy exclusions) changes the screening funnel at every open oncology site at once, so any enrolment-rate shift after this date is a policy effect, not a molecule effect.
channel-check divergencenews.google.com
Rare-disease designs lean hardest on eligibility relaxation and small-site networks, so the widening-to-activation squeeze should appear first and most cleanly here, giving the earliest read on whether the funnel or the site desk binds.
guidance-language deltanews.google.com
Next step
See how Discover can help you act on the sources behind it.
[withheld] — Clinical trial enrollment and prescreening operational data: candidate screening call transcripts/answers, recruitment-partner/site conversion performance, no-show risk scores, and de-identified prescreening logs across studies. Early-stage (5 employees), platform used across multiple studies and recruitment partners/sites — exact study/candidate counts not disclosed on page. Use cases: Clinical trial operations benchmarking, patient recruitment funnel optimization, no-show/dropout risk prediction modeling, recruitment-partner performance scoring
[withheld] — Proprietary clinical trial site-activation and enrollment-efficiency metrics (Site Effectiveness Index) derived from analysis of 2,145+ trials across 15 top global pharma sponsors, benchmarking site activation timing against enrollment capacity. Analysis spans 2,145 clinical trials across 15 top global pharma sponsors (30-60 sites per trial); company has ~12 employees. Use cases: Clinical trial site-activation benchmarking, CRO selection and oversight, enrollment-timeline forecasting, protocol design optimization, sponsor portfolio performance comparison
[withheld] — Decentralized, consented real-world patient cohort data: EMR/EHR-linked clinical records fused with patient-reported experience data, recruitment/screening funnel data, and post-launch outcomes across reusable 'ACCESS Cohorts'. 91 employees, $25M total funding (Series A), $3M revenue range; UK-based with NHS Digital Toolkit compliance implying access to UK NHS-linked patient populations. Use cases: Pharma launch-strategy validation, patient segmentation and positioning research, eligibility-criteria and trial-design optimization, post-market outcomes analysis, real-world evidence gener…
[withheld] — Clinical trial patient recruitment and prescreening data: EMR/EHR-derived eligibility screens, online/phone screening responses, lead-to-randomization funnel records, and campaign conversion analytics across many trials. 72 employees, $14.2M revenue range, prior M&A/acquisition activity; operates recruitment campaigns across many concurrent clinical trials. Use cases: Clinical trial recruitment funnel benchmarking, screen-failure root-cause analysis, patient recruitment campaign optimization models, site/vendor performance scoring
[withheld] — Regulatory-grade real-world healthcare data: de-identified electronic health records, laboratory results, and medical imaging curated from a network of 1,400+ healthcare system and provider sites (iRWD platform). 1,400+ healthcare system and provider sites in the iRWD network; 23 employees, $1.4M revenue range; publicly traded (Nasdaq: ONMD). Use cases: Clinical trial design support, oncology/rare disease/cardiology research, regulatory-grade real-world evidence generation, medical imaging AI model training, diagnostic AI development
[withheld] — Multimodal oncology and immuno-oncology patient data network: clinical records, digital pathology whole-slide images (H&E WSI), genomics, and other modalities sourced from 100+ partner hospitals. 100+ partner hospitals in 14 countries, 148 total partner sites, 13 indications across oncology/immuno-oncology, example cohort of 664 NSCLC patients — implies tens of thousands of richly annotated patient records overall. Use cases: Oncology drug development, biomarker discovery, clinical trial cohort identification and enrollment planning, multimodal AI model training (imaging + clinical + …
[withheld] — Clinical trial site-operations and compliance exhaust data: eTMF/eISF document exchange logs, site activation/startup timelines, eConsent records, site qualification and performance-by-therapy-area/geography metrics across a network of 65,000+ sites and 600+ sponsors. 65,000+ connected study sites, 600+ pharma/biotech sponsors, 90+ countries; 280 employees and $115.8M total funding (Series C). Use cases: Site activation benchmarking, CRO/sponsor operational performance analytics, site-selection and feasibility modeling, compliance/QA trend analysis, trial-startup cycle-t…